# US 2023/0056051 A1 · Activatable cytokine polypeptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056051 A1
- Document ID: US20230056051A1
- Status: Published application
- Kind: A1
- Application number: 17/934,811
- Filed: 2022-09-23
- Published: 2023-02-23
- Earliest claimed: 2019-11-14
- Assignees: Werewolf Therapeutics, Inc.
- Applicants: Werewolf Therapeutics, Inc.
- Inventors: William WINSTON; Daniel HICKLIN; Jose Andres SALEMERON-GARCIA; Heather BRODKIN; Cynthia SEIDEL-DUGAN
- Web page: https://patentgrep.com/patent/US20230056051A1

## CPC

- A61K 38/2013: {IL-2}
- C07K 14/55: IL-2
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/208: {IL-12}
- A61K 38/212: {IFN-alpha}
- A61K 38/215: {IFN-beta}
- A61K 38/217: {IFN-gamma}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4221: {CD20}
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6845: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/5434: {IL-12}
- C07K 14/57: IFN-gamma
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2887: {against CD20}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/50: containing protease site
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g. a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.

## Claims

### Claim at position 1

1-68. (canceled)

### Claim 69

A method of treating a cancer in a human subject comprising administering to the subject in need thereof an effective amount of therapeutic combination comprising a) an inducible cytokine polypeptide and b) a cellular therapy.

### Claim 70 (depends on 69)

The method of claim 69, where the cellular therapy comprises T-cell therapy.

### Claim 71

The method of 70, wherein the T-cell therapy comprises activated T cells.

### Claim 72 (depends on 70)

The method of claim 70, wherein the T-cell therapy comprises CAR-T cells.

### Claim 73 (depends on 69)

The method of claim 69, where the cellular therapy comprises NK cells.

### Claim 74 (depends on 69)

The method of claim 69, wherein the inducible cytokine polypeptide comprises IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-23, TGF, interferon alpha, interferon beta, interferon gamma, TNF, TGFbeta, CXCL10, CCL19, CCL20, CCL21, or a mutein, a variant, an active fragment, or a subunit of any of the foregoing.

### Claim 75 (depends on 69)

The method of claim 69, wherein the inducible cytokine polypeptide comprises IL-2.

### Claim 76 (depends on 69)

The method of claim 69, wherein the inducible cytokine polypeptide comprises IL-12.

### Claim 77 (depends on 69)

The method of claim 69, wherein the inducible cytokine polypeptide comprises one polypeptide chain, or two or more polypeptide chains.

### Claim 78 (depends on 75)

The method of claim 75, wherein the inducible cytokine polypeptide comprises a) a cytokine polypeptide; b) a cytokine blocking moiety that inhibits cytokine receptor activating activity of the cytokine polypeptide; and c) a half-life extension domain; wherein the cytokine polypeptide is operably linked to the cytokine blocking moiety through a first linker comprising a cleavable peptide and the cytokine blocking moiety is operably linked to the half-life extension domain through a second linker.

### Claim 79 (depends on 76)

The method of claim 76, wherein the cytokine blocking moiety is a ligand-binding domain or fragment of a cognate receptor for the cytokine polypeptide or an antibody or antigen-binding fragment of an antibody that binds the cytokine polypeptide.

### Claim 80 (depends on 76)

The method of claim 76, wherein half-life extension domain is an immunoglobulin Fc, human serum albumin or a fragment thereof that binds neonatal Fc receptor, or an antigen-binding portion of an antibody that binds to FcRn or to human serum albumin.

### Claim 81 (depends on 76)

The method of claim 76, wherein a) the cytokine polypeptide is an IL-2 polypeptide; b) the cytokine blocking moiety is a IL-2-binding domain or fragment of an IL-2 receptor or an antibody or antigen-binding fragment of an antibody that binds IL-2; and c) the half-life extension domain is an immunoglobulin Fc, human serum albumin or a fragment thereof that binds neonatal Fc receptor, or an antigen-binding portion of an antibody that binds to FcRn or to human serum albumin.

### Claim 82 (depends on 79)

The method of claim 79, wherein the cytokine blocking moiety is a IL-2-binding domain or fragment of an IL-2 receptor, and the IL-2 receptor comprises IL-2Rα (CD25), IL-2Rβ (CD122), IL-2Rγ (CD132) or combinations thereof.

### Claim 83 (depends on 79)

The method of claim 79, wherein the cytokine blocking moiety is an antibody or antigen-binding fragment of an antibody that binds IL-2.

### Claim 84 (depends on 76)

The method of claim 76, wherein a) the cytokine polypeptide is an IL-12 polypeptide; b) the cytokine blocking moiety is a IL-12-binding domain or fragment of an IL-12 receptor or an antibody or antigen-binding fragment of an antibody that binds IL-12; and c) the half-life extension domain is an immunoglobulin Fc, human serum albumin or a fragment thereof that binds neonatal Fc receptor, or an antigen-binding portion of an antibody that binds to FcRn or to human serum albumin.

### Claim 85 (depends on 79)

The method of claim 79, wherein the cytokine blocking moiety is a IL-12-binding domain or fragment of an IL-12 receptor, and the IL-12 receptor comprises IL-12Rβ1, IL-12Rβ2 or combinations thereof.

### Claim 86 (depends on 79)

The method of claim 79, wherein the cytokine blocking moiety is an antibody or antigen-binding fragment of an antibody that binds IL-12.

### Claim 87 (depends on 69)

The method of claim 69, wherein the cancer is characterized by solid tumors.

### Claim 88 (depends on 69)

The method of claim 69, wherein the inducible cytokine polypeptide comprises a substrate for a protease and has at least about 10× less cytokine receptor activating activity relative to the polypeptide that contains the cytokine that is produced by protease cleavage of the inducible cytokine polypeptide.

### Claim 89

A therapeutic combination comprising a) an inducible cytokine polypeptide and b) a cellular therapy, in an amount effective to treat cancer in a human subject.

### Claim 90

A therapeutic combination comprising a) an inducible cytokine polypeptide, b) a cellular therapy, and c) an immune-oncology agent, in an amount effective to treat cancer in a human subject.
